Genetic screening of Alzheimer's disease genes in Iberian and African samples y...

• Autor(es): Guerreiro, Rita João ; Baquero, Miquel ; Blesa, Rafael ; Boada, Mercè ; Brás, José Miguel ; Bullido, Maria. J. ; Calado, Ana ; Crook, Richard ; Ferreira, Carla ; Frank, Ana ; Gómez-Isla, Teresa ; Hernández, Isabel ; Lleó, Alberto ; Machado, Álvaro ; Martínez- Lage, Pablo ; Masdeu, José ; Molina-Porcel, Laura ; Molinuevo, José L. ; Pastor, Pau ; Pérez-Tur, Jordi ; Relvas, Rute ; Oliveira, Catarina Resende ; Ribeiro, Maria Helena ; Rogaeva, Ekaterina ; Sá, Alfredo ; Samaranch, Lluís ; Sánchez-Valle, Raquel ; Santana, Isabel ; Tàrraga, Lluís ; Valdivieso, Fernando ; Singleton, Andrew ; Hardy, John ; Clarimón, Jordi
• Data: 2010
• Identificador Persistente: http://hdl.handle.net/10316/20129
• Origem: Estudo Geral - Universidade de Coimbra
• Assunto(s): Early-onset Alzheimer’s disease; Presenilins; APP; Mutations
• Tipo de Documento: Artigo
• Idioma: Inglês

Descrição

Mutations in three genes (PSEN1, PSEN2, and APP) have been identified in patients with early-onset (<65years) Alzheimer’s disease (AD). We performed a screening for mutations in the coding regions of presenilins, as well as exons 16 and 17 of the APP gene in a total of 231 patients from the Iberian peninsular with a clinical diagnosis of early onset AD (mean age at onset of 52.9 years; range 31– 64). We found three novel mutations in PSEN1, one novel mutation in PSEN2, and a novel mutation in the APP gene. Four previously described mutations in PSEN1 were also found. The same analysis was carried in 121 elderly healthy controls from the Iberian peninsular, and a set of 130 individuals from seven African populations belonging to the Centre d’Etude du Polymorphisme Humain-Human Genome Diversity Panel (CEPH-HGDP), in order to determine the extent of normal variability in these genes. Interestingly, in the latter series, we found five new nonsynonymous changes in all three genes and a presenilin 2 variant (R62H) that has been previously related to AD. In some of these mutations, the pathologic consequence is uncertain and needs further investigation. To address this question we propose and use a systematic algorithm to classify the putative pathology of AD mutations.